New study monitors UPLIZNA's effects on pregnancy in NMOSD patients
NCT ID NCT05909761
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 60 women with neuromyelitis optica spectrum disorder (NMOSD) who received UPLIZNA during pregnancy or within 6 months before conception. Researchers will collect data on pregnancy outcomes, including birth defects, preterm birth, and infant development over 10 years. The goal is to better understand the safety of UPLIZNA in pregnancy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University of Colorado Denver
RECRUITINGAurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can antimalarials be safely used in early pregnancy? a massive registry seeks answers
- Texts and local mentors: a new way to empower teen girls on contraception?
- Mindfulness during pregnancy: a new way to boost mental health and baby bonding?
- Teaching Moms-to-Be about seafood safety: a new weapon against toxic exposures?
- Can we improve emergency C-Sections for the sickest mothers?
- Can a simple blood test unlock the secrets of brain autoimmune diseases?